Published in Thromb Haemost on January 21, 2016
Subsequent Response of VWF and ADAMTS13 to Aortic Valve Replacement. J Atheroscler Thromb (2016) 0.75
PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab (2007) 7.19
Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med (2003) 5.33
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat (2009) 2.93
Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ Res (2011) 2.60
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med (2012) 2.51
A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology (2005) 2.38
Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med (2007) 2.32
Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit Care Med (2006) 2.21
Pivotal role of bedside Doppler echocardiography in the assessment of patients with acute heart failure and mitral regurgitation. Cardiology (2009) 2.03
Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert(®) HIT) for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol (2014) 2.01
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension (2008) 1.95
Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat (2007) 1.89
Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler Thromb Vasc Biol (2007) 1.85
Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res (2011) 1.85
Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol (2002) 1.81
Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation (2005) 1.78
Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood (2008) 1.72
Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med (2011) 1.66
Liver X receptor activation stimulates iron export in human alternative macrophages. Circ Res (2013) 1.66
Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica (2005) 1.63
Progressive cardiac conduction defect is the prevailing phenotype in carriers of a Brugada syndrome SCN5A mutation. J Cardiovasc Electrophysiol (2006) 1.63
New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One (2010) 1.59
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab (2004) 1.58
Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem (2007) 1.57
Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction. Circulation (2008) 1.56
Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med (2006) 1.56
A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial. Catheter Cardiovasc Interv (2012) 1.55
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood (2008) 1.54
Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood (2010) 1.53
Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis (2010) 1.52
Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood (2013) 1.51
A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood (2009) 1.51
Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A (2008) 1.51
Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood (2007) 1.47
Decellularized heart valve as a scaffold for in vivo recellularization: deleterious effects of granulocyte colony-stimulating factor. J Thorac Cardiovasc Surg (2006) 1.46
Comparison of blood activation in the wound, active vent, and cardiopulmonary bypass circuit. Ann Thorac Surg (2008) 1.45
Construction of a tube-shaped tracheal substitute using fascial flap-wrapped revascularized allogenic aorta. Eur J Cardiothorac Surg (2011) 1.44
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood (2012) 1.43
Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis (2007) 1.42
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood (2013) 1.36
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood (2005) 1.35
Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem (2005) 1.34
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One (2010) 1.33
Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood (2005) 1.33
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood (2005) 1.32
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood (2008) 1.30
Iliopsoas hematoma in patients with hemophilia: a single-center study. Joint Bone Spine (2007) 1.27
The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood (2011) 1.24
P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood (2006) 1.24
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) (2004) 1.21
Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem (2003) 1.20
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood (2006) 1.20
Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood (2003) 1.17
Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem (2003) 1.16
The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol (2007) 1.16
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica (2012) 1.13
Staphylococcus aureus protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. FEBS J (2006) 1.13
The "thymopericardial fat flap": a versatile flap in thoracic and cardiovascular surgery. J Thorac Cardiovasc Surg (2010) 1.11
The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction. J Immunol (2008) 1.07
Management of dental extractions in patients with bleeding disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2002) 1.07
Combined repair of pectus excavatum and cardiopulmonary bypass surgery. What is the best strategy? Ann Thorac Surg (2013) 1.06
Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood (2008) 1.05
Echocardiography predictors and prognostic value of pulmonary artery systolic pressure in chronic organic mitral regurgitation. Heart (2010) 1.05
Thrombotic thrombocytopenic purpura: medical and biological monitoring of six pregnancies. Eur J Obstet Gynecol Reprod Biol (2003) 1.04
LDL-receptor-related protein regulates beta2-integrin-mediated leukocyte adhesion. Blood (2004) 1.04
Cancer awareness in atypical thrombotic microangiopathies. Oncologist (2009) 1.03
The proteome and secretome of human arterial smooth muscle cells. Proteomics (2005) 1.02
Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood (2006) 1.02
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol (2008) 1.02
Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood (2012) 1.01
Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr Nephrol (2008) 1.01
Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood (2010) 0.99
Spectrum of the mutations in Bernard-Soulier syndrome. Hum Mutat (2014) 0.97
The alpha -chains of C4b-binding protein mediate complex formation with low density lipoprotein receptor-related protein. J Biol Chem (2001) 0.97
Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: a study on delivery efficiency. J Cell Mol Med (2012) 0.96
High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) (2003) 0.96
von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate. Blood (2003) 0.96
Binding of low density lipoprotein to platelet apolipoprotein E receptor 2' results in phosphorylation of p38MAPK. J Biol Chem (2004) 0.94
Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood (2003) 0.93
Unlike PPARgamma, PPARalpha or PPARbeta/delta activation does not promote human monocyte differentiation toward alternative macrophages. Biochem Biophys Res Commun (2009) 0.93
The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood (2013) 0.93
Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide. Ann Intern Med (2004) 0.93
Central extracorporeal life support in pheochromocytoma crisis. Ann Thorac Surg (2012) 0.93